NICE updates its cost-effectiveness threshold. Discover the implications of this change for the UK HTA, patient access, and pricing strategy. Read here.
Explore scalable direct-to-patient (DTP) models that improve affordability, time-to-therapy, and patient engagement with a strategic, data-driven approach. Read here.
In July 2025, the Italian Medicines Agency (AIFA) revised its drug innovativeness criteria, ending “conditional” status and prioritizing rare and ultra-rare diseases. Read here.
Experts Ryan Subhan and Emily Phillips highlight early planning, market education, and overcoming challenges in launching rare disease therapies. Watch now.
This video highlights the challenges of launching an expensive therapy for a rare disease, focusing on partnerships, planning, and tailored care. Watch now.
The video highlights the crucial role of advocacy groups and the importance of early, strategic planning for successfully launching rare disease treatments. Watch now.
Essential Strategies for Manufacturers to Adapt Financially and Operationally Amidst Evolving Regulatory Landscapes and Market Pressures. Read the article to find out more.
The Centers for Medicare & Medicaid Services (CMS) just announced the first set of drugs and biologics for price negotiations to be effective 2026. Read the article to find out more.
In this video conversation with commercial experts from Herspiegel you'll learn how considering commercial viability early in the development process can significantly improve the launch success of new drugs by pharmaceutical and biotech companies.
In this video conversation with commercial experts from Herspiegel you'll learn how considering commercial viability early in the development process can significantly improve the launch success of new drugs by pharmaceutical and biotech companies.
In this video conversation with commercial experts from Herspiegel you'll learn how considering commercial viability early in the development process can significantly improve the launch success of new drugs by pharmaceutical and biotech companies.
In this video conversation with commercial experts from Herspiegel you'll learn how considering commercial viability early in the development process can significantly improve the launch success of new drugs by pharmaceutical and biotech companies.
In this video conversation with commercial experts from Herspiegel you'll learn how considering commercial viability early in the development process can significantly improve the launch success of new drugs by pharmaceutical and biotech companies.
Currently, Medicaid rebates paid by drug manufacturers are capped at the quarterly Average Manufacturer’s Price (AMP) for each drug/biologic. The removal of the cap means ...
In this post, we discuss different approaches that aim to incite competition between branded and generic drug products, as well as an example demonstrating the potential impact of these policies.
This is the first in a four-part series where we will explore the issue of government intervention in drug costs. In this first post, we introduce a few commonly mentioned tactics, two of which we will dig deeper into in subsequent posts.
The Centers for Medicare & Medicaid Services (CMS) just announced the first set of drugs and biologics for price negotiations to be effective 2026. Read the article to find out more.
Since CMS announced the first ten drugs selected for price negotiation on August 29th, 2023, primary manufacturers had until October 1st, 2023, to sign agreements to participate in the Price Negotiation Program. Read the article to find out more.
We helped our major pharmaceutical client equip it organization to offer value-based contracts to support access for a new specialty drug. Read the case study.
Discover how our tailored reimbursement strategy propelled a small biotech's innovative ophthalmic product to exceed launch forecasts by 60% in patient treatment.
We partnered with our client to establish a narrative that increased availability results in improvements in health outcomes and downstream cost savings. Read the case study.
We helped a client’s new product team plan their US and EU access strategies for a novel compound with potential in both rare and more common respiratory conditions. Read the case study.
A global pharmaceutical company worked with us to plan their European Union (EU) access strategy for a novel oncolytic drug based on a new formulation. Read the case study.
Our client, a mid-sized biopharmaceutical company, aimed to introduce a new asset into the highly competitive Parkinson's disease category. Read the case study.
Discover how Most Favored Nation (MFN) policy impacts U.S. drug pricing and market access in 2025, from CMS enforcement to launch planning. Get the whitepaper now.
The IRA will make many improvements to the Medicare program overall, and many on the pharmaceutical side have been mainly focused on preparing for the Medicare Drug Price Negotiation Program. Download this paper to understand the current timelines and guidance.
NICE updates its cost-effectiveness threshold. Discover the implications of this change for the UK HTA, patient access, and pricing strategy. Read here.
Explore scalable direct-to-patient (DTP) models that improve affordability, time-to-therapy, and patient engagement with a strategic, data-driven approach. Read here.
In July 2025, the Italian Medicines Agency (AIFA) revised its drug innovativeness criteria, ending “conditional” status and prioritizing rare and ultra-rare diseases. Read here.
Discover how Most Favored Nation (MFN) policy impacts U.S. drug pricing and market access in 2025, from CMS enforcement to launch planning. Get the whitepaper now.
Experts Ryan Subhan and Emily Phillips highlight early planning, market education, and overcoming challenges in launching rare disease therapies. Watch now.
This video highlights the challenges of launching an expensive therapy for a rare disease, focusing on partnerships, planning, and tailored care. Watch now.
The video highlights the crucial role of advocacy groups and the importance of early, strategic planning for successfully launching rare disease treatments. Watch now.
We helped our major pharmaceutical client equip it organization to offer value-based contracts to support access for a new specialty drug. Read the case study.
Discover how our tailored reimbursement strategy propelled a small biotech's innovative ophthalmic product to exceed launch forecasts by 60% in patient treatment.
We partnered with our client to establish a narrative that increased availability results in improvements in health outcomes and downstream cost savings. Read the case study.
We helped a client’s new product team plan their US and EU access strategies for a novel compound with potential in both rare and more common respiratory conditions. Read the case study.
Essential Strategies for Manufacturers to Adapt Financially and Operationally Amidst Evolving Regulatory Landscapes and Market Pressures. Read the article to find out more.
The Centers for Medicare & Medicaid Services (CMS) just announced the first set of drugs and biologics for price negotiations to be effective 2026. Read the article to find out more.
In this video conversation with commercial experts from Herspiegel you'll learn how considering commercial viability early in the development process can significantly improve the launch success of new drugs by pharmaceutical and biotech companies.
In this video conversation with commercial experts from Herspiegel you'll learn how considering commercial viability early in the development process can significantly improve the launch success of new drugs by pharmaceutical and biotech companies.
In this video conversation with commercial experts from Herspiegel you'll learn how considering commercial viability early in the development process can significantly improve the launch success of new drugs by pharmaceutical and biotech companies.
In this video conversation with commercial experts from Herspiegel you'll learn how considering commercial viability early in the development process can significantly improve the launch success of new drugs by pharmaceutical and biotech companies.
In this video conversation with commercial experts from Herspiegel you'll learn how considering commercial viability early in the development process can significantly improve the launch success of new drugs by pharmaceutical and biotech companies.
Currently, Medicaid rebates paid by drug manufacturers are capped at the quarterly Average Manufacturer’s Price (AMP) for each drug/biologic. The removal of the cap means ...
A global pharmaceutical company worked with us to plan their European Union (EU) access strategy for a novel oncolytic drug based on a new formulation. Read the case study.
Our client, a mid-sized biopharmaceutical company, aimed to introduce a new asset into the highly competitive Parkinson's disease category. Read the case study.
In this post, we discuss different approaches that aim to incite competition between branded and generic drug products, as well as an example demonstrating the potential impact of these policies.
This is the first in a four-part series where we will explore the issue of government intervention in drug costs. In this first post, we introduce a few commonly mentioned tactics, two of which we will dig deeper into in subsequent posts.
The Centers for Medicare & Medicaid Services (CMS) just announced the first set of drugs and biologics for price negotiations to be effective 2026. Read the article to find out more.
Since CMS announced the first ten drugs selected for price negotiation on August 29th, 2023, primary manufacturers had until October 1st, 2023, to sign agreements to participate in the Price Negotiation Program. Read the article to find out more.
The IRA will make many improvements to the Medicare program overall, and many on the pharmaceutical side have been mainly focused on preparing for the Medicare Drug Price Negotiation Program. Download this paper to understand the current timelines and guidance.
